Aquarius Surgical Technologies Announces Appointment of Mr. Gordon Willox as President & CTO, and the Closing of Funding Transaction
November 28, 2018 04:00 ET
|
Surgical Lasers Inc.
TORONTO, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Aquarius Surgical Technologies Inc. (ASTI – CSE) (“the Corporation”) is pleased to announce that Mr. Gordon Willox, has been appointed to the position of...
Exosome Diagnostics’ Second Prospective Validation Study of EPI to be Highlighted at American Urological Association (AUA) Annual Meeting Press Briefing in San Francisco, CA
May 17, 2018 12:47 ET
|
Exosome Diagnostics
Waltham, MA, May 17, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics’ novel urine-based prostate cancer liquid biopsy biomarker test, ExoDx™ Prostate(IntelliScore) or EPI, was selected out of 3000...
Exosome Diagnostics Continues to Expand Coverage Reach for its EPI Test
May 09, 2018 08:03 ET
|
Exosome Diagnostics
Waltham, MA, May 09, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. has continued to make significant progress in expanding contracts to provide laboratory services and ExoDx®...
Exosome Diagnostics Expands National Sales Team after Blockbuster Quarter with its Flagship Diagnostic, ExoDx Prostate®(IntelliScore) (EPI) Test
May 08, 2018 06:30 ET
|
Exosome Diagnostics
Waltham, MA, May 08, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. has expanded its urology salesforce within the United States after a successful first quarter commercial launch of ExoDx...
Poseida Therapeutics Presents Stem Cell Memory CAR-T Therapy for Prostate Cancer at 2018 Keystone Symposia on Emerging Cellular Therapies
February 14, 2018 08:00 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies,...
Exosome Diagnostics Significantly Expands Access and Coverage for its EPI Prostate Cancer Test through Agreement with FedMed
February 01, 2018 07:35 ET
|
Exosome Diagnostics
Waltham, MA, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., announced today that it has executed an agreement to provide its prostate cancer risk assessment test, ExoDx®...
EDAP Announces CMS Approval of New Reimbursement Code for HIFU Ablation of the Prostate
May 22, 2017 09:00 ET
|
EDAP TMS SA
Billing code will take effect July 1st, 2017 LYON, France, May 22, 2017 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that the...
The Fight Against Prostate Cancer: What Men Need to Know
December 08, 2016 09:00 ET
|
Bio-Reference Laboratories, Inc.
NEW YORK, Dec. 08, 2016 (GLOBE NEWSWIRE) -- Prostate cancer is the second most common cancer among men, and it is estimated that nearly three million men are living with the disease in the United...
Holy Name Medical Center First in the Northeast to Offer Magellan(TM) Robotic System
November 19, 2015 06:11 ET
|
Holy Name Medical Center
TEANECK, N.J., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Physicians at Holy Name Medical Center are the first in the Northeast to use the Magellan™ Robotic System, which enables them to perform complex,...
ProstateHealthGuide.org launched for Prostate Health Month
September 02, 2015 14:25 ET
|
Men's Health Network
WASHINGTON, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Men's Health Network has launched a new website in celebration of Prostate Health Month this September. The website- www.prostatehealthguide.com -will...